Quick Answer
LakeShore Biopharma Co., Ltd. reported Long-Term Debt of $23.50 million for fiscal year 2025.
LakeShore Biopharma Co., Ltd. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $23.50M | -76.3% |
| 2024 | $98.98M | -66.3% |
| 2023 | $293.79M | +15.7% |
| 2022 | $253.93M | — |
- LakeShore Biopharma Co., Ltd. showed a decrease of -76.3% in Long-Term Debt compared to the prior fiscal year.
- Over the 2022–2025 period, LakeShore Biopharma Co., Ltd.’s long-term debt has declined by 90.7% (from $253.93 million to $23.50 million).
- The most recent figure is from LakeShore Biopharma Co., Ltd.’s fiscal year 2025 report (Form 20-F), filed with the SEC on July 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: